Expert Review of Clinical Immunology最新文献_第9页

Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma. 肿瘤相关巨噬细胞是黑色素瘤当前和未来疗法的关键因素和目标。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-08-01 Epub Date: 2024-03-27 DOI: 10.1080/1744666X.2024.2326626

Shabana Habib, Gabriel Osborn, Zena Willsmore, Min Waye Chew, Sophie Jakubow, Amanda Fitzpatrick, Yin Wu, Khushboo Sinha, Hawys Lloyd-Hughes, Jenny L C Geh, Alastair D MacKenzie-Ross, Sean Whittaker, Victoria Sanz-Moreno, Katie E Lacy, Sophia N Karagiannis, Rebecca Adams

{"title":"Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma.","authors":"Shabana Habib, Gabriel Osborn, Zena Willsmore, Min Waye Chew, Sophie Jakubow, Amanda Fitzpatrick, Yin Wu, Khushboo Sinha, Hawys Lloyd-Hughes, Jenny L C Geh, Alastair D MacKenzie-Ross, Sean Whittaker, Victoria Sanz-Moreno, Katie E Lacy, Sophia N Karagiannis, Rebecca Adams","doi":"10.1080/1744666X.2024.2326626","DOIUrl":"10.1080/1744666X.2024.2326626","url":null,"abstract":"Introduction: Despite the success of immunotherapies for melanoma in recent years, there remains a significant proportion of patients who do not yet derive benefit from available treatments. Immunotherapies currently licensed for clinical use target the adaptive immune system, focussing on Tcell interactions and functions. However, the most prevalent immune cells within the tumor microenvironment (TME) of melanoma are macrophages, a diverse immune cell subset displaying high plasticity, to which no current therapies are yet directly targeted. Macrophages have been shown not only to activate the adaptive immune response, and enhance cancer cell killing, but, when influenced by factors within the TME of melanoma, these cells also promote melanoma tumorigenesis and metastasis.Areas covered: We present a review of the most up-to-date literatureavailable on PubMed, focussing on studies from within the last 10 years. We also include data from ongoing and recent clinical trials targeting macrophages in melanoma listed on clinicaltrials.gov.Expert opinion: Understanding the multifaceted role of macrophages in melanoma, including their interactions with immune and cancer cells, the influence of current therapies on macrophage phenotype and functions and how macrophages could be targeted with novel treatment approaches, are all critical for improving outcomes for patients with melanoma.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"895-911"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy. 癌症中与肿瘤相关的三级淋巴结构：对免疫疗法的影响。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-08-01 Epub Date: 2024-07-16 DOI: 10.1080/1744666X.2024.2380892

Mireille Langouo Fontsa, Francine Padonou, Karen Willard-Gallo

{"title":"Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy.","authors":"Mireille Langouo Fontsa, Francine Padonou, Karen Willard-Gallo","doi":"10.1080/1744666X.2024.2380892","DOIUrl":"10.1080/1744666X.2024.2380892","url":null,"abstract":"Introduction: Tertiary lymphoid structures (TLS) arise at chronic inflammatory sites where they function as miniature lymph nodes to generate immune responses, which can be beneficial or detrimental, in diseases as diverse as autoimmunity, chronic infections and cancer. A growing number of studies show that a TLS presence in tumors from cancer patients treated with immune checkpoint inhibitors is closely linked with improved clinical outcomes. TLS may foster the generation of specific anti-tumor immune responses and immunological memory that recognizes a patient's own tumor. Due to repeated rounds of chronic inflammation, some tumor-associated TLS may be immunologically inactive, with immune checkpoint inhibitors functioning to revitalize them through pathway activation.Areas covered: This review summarizes work on TLS and how they mediate immune responses in human tumors. We also explore TLS as potential prognostic and predictive biomarkers for immunotherapy.Expert opinion: The presence of TLS in human tumors has been linked with a better clinical prognosis, response to treatment(s) and overall survival. TLS provide a structured microenvironment for the activation, expansion and maturation of immune cells at the tumor site. These activities can enhance the efficacy of immunotherapeutic treatments such as checkpoint inhibitors and cancer vaccines by revitalizing local anti-tumor immunity.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"839-847"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes? FoxP3 与肿瘤微环境和癌症预后有什么关系？

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-08-01 Epub Date: 2024-03-25 DOI: 10.1080/1744666X.2024.2334258

Abdo Meyiah, Eyad Elkord

{"title":"What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?","authors":"Abdo Meyiah, Eyad Elkord","doi":"10.1080/1744666X.2024.2334258","DOIUrl":"10.1080/1744666X.2024.2334258","url":null,"abstract":"Introduction: Forkhead box P3 (FoxP3) transcription factor plays critical roles in controlling immune responses and cancer progression in different cancers. FoxP3 expression within the tumor microenvironment (TME) may influence clinical outcomes negatively or positively, and it could play dual roles in cancer, either by promoting or inhibiting tumor development and progression. Some studies reported that high levels of FoxP3 could be associated with tumor progression and worse prognosis, while others reported contradictory results.Areas covered: In this special report, we present a brief account on the role and function of FoxP3 in the TME, and its contribution to the clinical outcomes of cancer patients. Importantly, we give insights on the potential factors that could contribute to different clinical outcomes in cancer patients.Expert opinion: Different studies showed that FoxP3 expression can be associated with bad prognoses in cancer patients. However, FoxP3 could have opposing roles by enhancing cancer progression or regression. Location and expression of FoxP3 in T cells or tumor cells can have different impacts on cancer prognoses. Different factors should be considered to establish FoxP3 as a more robust prognostic biomarker and a potential therapeutic target for enhancing anti-tumor immunity and improving clinical outcomes of cancer patients.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"803-809"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140184143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR-T cell technologies that interact with the tumour microenvironment in solid tumours. 与实体瘤的肿瘤微环境相互作用的 CAR-T 细胞技术。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-08-01 Epub Date: 2024-07-17 DOI: 10.1080/1744666X.2024.2380894

Chelsea Alice Taylor, Maya Glover, John Maher

{"title":"CAR-T cell technologies that interact with the tumour microenvironment in solid tumours.","authors":"Chelsea Alice Taylor, Maya Glover, John Maher","doi":"10.1080/1744666X.2024.2380894","DOIUrl":"10.1080/1744666X.2024.2380894","url":null,"abstract":"Introduction: Chimeric antigen receptor (CAR) T-cells have emerged as a ground-breaking therapy for the treatment of hematological malignancies due to their capacity for rapid tumor-specific killing and long-lasting tumor immunity. However, the same success has not been observed in patients with solid tumors. Largely, this is due to the additional challenges imposed by safe and uniform target selection, inefficient CAR T-cell access to sites of disease and the presence of a hostile immunosuppressive tumor microenvironment.Areas covered: Literature was reviewed on the PubMed database from the first description of a CAR by Kuwana, Kurosawa and colleagues in December 1987 through to the present day. This literature indicates that in order to tackle solid tumors, CAR T-cells can be further engineered with additional armoring strategies that facilitate trafficking to and infiltration of malignant lesions together with reversal of suppressive immune checkpoints that operate within solid tumor lesions.Expert opinion: In this review, we describe a number of recent advances in CAR T-cell technology that set out to combat the problems imposed by solid tumors including tumor recruitment, infiltration, immunosuppression, metabolic compromise, and hypoxia.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"849-871"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colorectal medullary carcinoma: a pathological subtype with intense immune response and potential to benefit from immune checkpoint inhibitors. 结直肠髓样癌：具有强烈免疫反应的病理亚型，有可能从免疫检查点抑制剂中获益。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-08-01 Epub Date: 2024-03-13 DOI: 10.1080/1744666X.2024.2328746

Haoyi Zou, Chao Liu, Yuli Ruan, Lin Fang, Tong Wu, Shuling Han, Tianjiao Dang, Hongxue Meng, Yanqiao Zhang

{"title":"Colorectal medullary carcinoma: a pathological subtype with intense immune response and potential to benefit from immune checkpoint inhibitors.","authors":"Haoyi Zou, Chao Liu, Yuli Ruan, Lin Fang, Tong Wu, Shuling Han, Tianjiao Dang, Hongxue Meng, Yanqiao Zhang","doi":"10.1080/1744666X.2024.2328746","DOIUrl":"10.1080/1744666X.2024.2328746","url":null,"abstract":"Introduction: Different pathological types of colorectal cancer have distinguished immune landscape, and the efficacy of immunotherapy will be completely different. Colorectal medullary carcinoma, accounting for 2.2-3.2%, is characterized by massive lymphocyte infiltration. However, the attention to the immune characteristics of colorectal medullary carcinoma is insufficient.Area covered: We searched the literature about colorectal medullary carcinoma on PubMed through November 2023to investigate the hallmarks of colorectal medullary carcinoma's immune landscape, compare medullary carcinoma originating from different organs and provide theoretical evidence for precise treatment, including applying immunotherapy and BRAF inhibitors.Expert opinion: Colorectal medullary carcinoma is a pathological subtype with intense immune response, with six immune characteristics and has the potential to benefit from immunotherapy. Mismatch repair deficiency, ARID1A missing and BRAF V600E mutation often occurs. IFN-γ pathway is activated and PD-L1 expression is increased. Abundant lymphocyte infiltration performs tumor killing function. In addition, BRAF mutation plays an important role in the occurrence and development, and we can consider the combination of BRAF inhibitors and immunotherapy in patients with BRAF mutant. The exploration of colorectal medullary carcinoma will arouse researchers' attention to the correlation between pathological subtypes and immune response, and promote the process of precise immunotherapy.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"997-1008"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune-scoring in head and neck squamous cell carcinoma: a scoping review. 头颈部鳞状细胞癌的免疫评分：范围界定综述。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-08-01 Epub Date: 2023-09-29 DOI: 10.1080/1744666X.2023.2262140

Raha Zamani, Nima Rezaei

{"title":"Immune-scoring in head and neck squamous cell carcinoma: a scoping review.","authors":"Raha Zamani, Nima Rezaei","doi":"10.1080/1744666X.2023.2262140","DOIUrl":"10.1080/1744666X.2023.2262140","url":null,"abstract":"Introduction: Head and neck squamous cell carcinomas (HNSCCs) have an increasing incidence, high recurrence, and an overall unfavorable prognosis despite numerous treatment options. The distinct immune landscape of HNSCC suggests a potential for immune-related biomarkers to aid classification and treatment planning.Areas covered: Immunoscore, a multiplex measure of tumor-infiltrating immune cells, is currently approved in colorectal carcinoma and is under investigation in various other cancer types. Recent studies have tried to implement the immunoscore and other novel immune cell-based scoring systems in HNSCC as predictors of survival. This study provides an overview of tumor-infiltrating immune cells and their prognostic significance, as well as a comparative summary of studies introducing an immunoscore in HNSCC.Expert opinion: With sufficient insight of the current literature, future studies could lead to the definition and validation of a new immune-based classification system for HNSCC. Such a classification strategy could be the basis for patient selection and, thus, optimize treatment outcomes and reduce unwanted complications. The heterogeneity of HNSCC subtypes, as well as the intratumoral variability of immune infiltrates, should be accounted for in the immunoscore.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1009-1017"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41117749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiphospholipid antibodies and the risk of adverse pregnancy outcomes in patients with systemic lupus erythematosus: a systematic review and meta-analysis. 抗磷脂抗体与系统性红斑狼疮患者不良妊娠结局的风险：系统回顾和荟萃分析。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-07-01 Epub Date: 2024-03-11 DOI: 10.1080/1744666X.2024.2324005

Jinge Huang, Qingmiao Zhu, Baizhou Wang, Hanzheng Wang, Zhijun Xie, Xingyu Zhu, Ting Zhao, Zi Yang

{"title":"Antiphospholipid antibodies and the risk of adverse pregnancy outcomes in patients with systemic lupus erythematosus: a systematic review and meta-analysis.","authors":"Jinge Huang, Qingmiao Zhu, Baizhou Wang, Hanzheng Wang, Zhijun Xie, Xingyu Zhu, Ting Zhao, Zi Yang","doi":"10.1080/1744666X.2024.2324005","DOIUrl":"10.1080/1744666X.2024.2324005","url":null,"abstract":"Objective: This article aims to evaluate the magnitude of adverse pregnancy outcomes (APOs) risks associated with different antiphospholipid antibody (aPL) profiles in women with systemic lupus erythematosus (SLE).Methods: Multiple databases were investigated to identify articles that explored the relationship between aPLs and APOs in SLE patients. A random effects model was used for calculating pooled odds ratios (OR). Stata version 15.0 was utilized to conduct the meta-analysis.Results: There were 5234 patients involved in 30 studies. Overall aPL was linked to an increased incidence of any kind of APOs, fetal loss, and preterm birth. Any kind of APOs and preterm delivery were more common in patients with lupus anticoagulant (LA) positive. Anticardiolipin antibody (aCL) was associated with an increased risk of any kind of APOs and fetal loss. The association between aCL-IgM and fetal loss was also significant. Patients with anti-beta2-glycoprotein1 antibody (antiβ2GP1) positivity had an increased risk of fetal loss.Conclusions: Both LA and aCL were risk factors of APOs in patients with SLE. Not only ACL, particularly aCL-IgM, but antiβ2GP1 were associated with an increased risk of fetal loss, while LA appeared to indicate the risk of preterm birth.PROSPERO (CRD42023388122).","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"793-801"},"PeriodicalIF":3.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons. ANCA相关血管病的治疗策略：从标准方案到未来展望。

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-07-01 Epub Date: 2024-03-06 DOI: 10.1080/1744666X.2024.2326628

Francesco Reggiani, Matteo Stella, Marta Calatroni, Renato Alberto Sinico

{"title":"Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons.","authors":"Francesco Reggiani, Matteo Stella, Marta Calatroni, Renato Alberto Sinico","doi":"10.1080/1744666X.2024.2326628","DOIUrl":"10.1080/1744666X.2024.2326628","url":null,"abstract":"Introduction: ANCA-associated vasculitides (AAV), classified into granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis represent a group of disorders characterized by necrotizing vasculitis of small vessels, endothelial injury and tissue damage. The outcomes and prognosis of AAV have undergone significant changes with the introduction of glucocorticoids (GCs) and other immunosuppressants (cyclophosphamide, azathioprine, methotrexate, and mycophenolate mofetil). The enhanced understanding of pathogenesis has subsequently led to the incorporation into clinical practice of drugs targeting specific therapeutic targets.Areas covered: After an extensive literature search of Pubmed, Medline, Embase of the most recent evidence, we provide an overview of available treatments, highlighting how newer drugs have integrated into standard protocols. Our review also explores potential new therapeutic targets, including B cell depletion and inhibition, T cell inhibition, complement inhibition, and IL-5 and IgE inhibition.Expert opinion: There is hope that the new treatment targets currently under study in AAV may enable a faster and more lasting clinical response, ensuring the reduction of possible side effects from therapies. Moreover, numerous aspects necessitate further exploration in the future, such as tailoring of GCs, integration of GCs-sparing agents, efficacy of combination therapy, optimal maintenance therapy, to reduce organ-damage and improve quality of life.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"765-780"},"PeriodicalIF":4.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy. 克服 CAR-T 细胞疗法后原发性耐药性和复发的挑战。

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-07-01 Epub Date: 2024-05-14 DOI: 10.1080/1744666X.2024.2349738

Alexandra Dreyzin, Alexander W Rankin, Katia Luciani, Tatyana Gavrilova, Nirali N Shah

{"title":"Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.","authors":"Alexandra Dreyzin, Alexander W Rankin, Katia Luciani, Tatyana Gavrilova, Nirali N Shah","doi":"10.1080/1744666X.2024.2349738","DOIUrl":"10.1080/1744666X.2024.2349738","url":null,"abstract":"Introduction: While CAR T-cell therapy has led to remarkable responses in relapsed B-cell hematologic malignancies, only 50% of patients ultimately have a complete, sustained response. Understanding the mechanisms of resistance and relapse after CAR T-cell therapy is crucial to future development and improving outcomes.Areas covered: We review reasons for both primary resistance and relapse after CAR T-cell therapies. Reasons for primary failure include CAR T-cell manufacturing problems, suboptimal fitness of autologous T-cells themselves, and intrinsic features of the underlying cancer and tumor microenvironment. Relapse after initial response to CAR T-cell therapy may be antigen-positive, due to CAR T-cell exhaustion or limited persistence, or antigen-negative, due to antigen-modulation on the target cells. Finally, we discuss ongoing efforts to overcome resistance to CAR T-cell therapy with enhanced CAR constructs, manufacturing methods, alternate cell types, combinatorial strategies, and optimization of both pre-infusion conditioning regimens and post-infusion consolidative strategies.Expert opinion: There is a continued need for novel approaches to CAR T-cell therapy for both hematologic and solid malignancies to obtain sustained remissions. Opportunities for improvement include development of new targets, optimally combining existing CAR T-cell therapies, and defining the role for adjunctive immune modulators and stem cell transplant in enhancing long-term survival.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"745-763"},"PeriodicalIF":4.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11180598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preventing fibrosis in IBD: update on immune pathways and clinical strategies. 预防 IBD 纤维化：免疫途径和临床策略的最新进展。

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-07-01 Epub Date: 2024-03-21 DOI: 10.1080/1744666X.2024.2330604

Jie Wang, Bo Yang, Jyotsna Chandra, Andrei Ivanov, J Mark Brown, Florian Rieder

{"title":"Preventing fibrosis in IBD: update on immune pathways and clinical strategies.","authors":"Jie Wang, Bo Yang, Jyotsna Chandra, Andrei Ivanov, J Mark Brown, Florian Rieder","doi":"10.1080/1744666X.2024.2330604","DOIUrl":"10.1080/1744666X.2024.2330604","url":null,"abstract":"Introduction: Intestinal fibrosis is a common and serious complication of inflammatory bowel diseases (IBD) driving stricture formation in Crohn's disease patients and leading to submucosal damage in ulcerative colitis. Recent studies provided novel insights into the role of immune and nonimmune components in the pathogenesis of intestinal fibrosis. Those new findings may accelerate the development of anti-fibrotic treatment in IBD patients.Areas covered: This review is designed to cover the recent progress in mechanistic research and therapeutic developments on intestinal fibrosis in IBD patients, including new cell clusters, cytokines, proteins, microbiota, creeping fat, and anti-fibrotic therapies.Expert opinion: Due to the previously existing major obstacle of missing consensus on stricture definitions and the absence of clinical trial endpoints, testing of drugs with an anti-fibrotic mechanism is just starting in stricturing Crohn's disease (CD). A biomarker to stratify CD patients at diagnosis without any complications into at-risk populations for future strictures would be highly desirable. Further investigations are needed to identify novel mechanisms of fibrogenesis in the intestine that are targetable and ideally gut specific.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"727-734"},"PeriodicalIF":4.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11180587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140109777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0